ClinicalTrials.gg
CompletedNCT04702451Tailored-AFUpdated Sep 12, 2025Results posted

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

An interventional study of Dispersion ablation + PVI and VX1 in Atrial Fibrillation, sponsored by Volta Medical. Completed at 26 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Volta Medical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in Atrial Fibrillation with a site in France — 63 open to participants now, 87 under way, 5 of them phase 3. Atrial Fibrillation · France.

Enrollment
69th of 193
377 · median 250
Started
2021
with 28 others
No phase
117 of 317
32 open now
Registered
213th of 317
by date

Among the 317 studies in Atrial Fibrillation with a site in France, this one is the 69th largest by enrollment of the 193 interventional ones that give a count, is one of 29 that started in 2021, is one of 117 with no phase, and was the 213th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

63 of the 317 studies in Atrial Fibrillation with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in Atrial Fibrillation with a site in France, or all of them as a file.
02

Study summary

Atrial Fibrillation (AF) ablation is typically performed in predefined anatomic regions of the left atrium without attempting to identify patient-specific areas of interest. This procedure is referred to as Pulmonary Vein Isolation (PVI).

The hypothesis in this Study is that a tailored ablation strategy targeting areas of spatio-temporal dispersion in combination with PVI is superior to an anatomical ablation strategy targeting PVI alone for the treatment of persistent AF.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Persistent Atrial Fibrillation
  • Catheter Ablation
  • Electrogram dispersion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years of age or older candidates for a first AF ablation
  • Symptomatic AF, to at least one antiarrhythmic medication
  • Persistent or long-standing persistent AF with documentation of (, Holter, physician's letter): AF duration of ≥ 3 months and ≤ 5 years (≥ 3 months and \< 1 year in the United States) or 1 effective cardioversion followed by AF recurrence lasting ≥ 3 months
  • Continuous anticoagulation with warfarin ( 2-3) or NOAC for > 4 weeks prior to ablation
  • Patients must be able and willing to provide written to participate in the clinical trial
  • At least 60% of patients (224 patients) in persistent AF ≥ 6 months including at least 15% (56 patients) of long-standing persistent AF ≥ 12 months

Exclusion criteria

Exclusion Criteria:

  • Paroxysmal and short-standing AF \< 3 months
  • Long-standing persistent AF > 5 years (≥ 1 year in the United States)
  • ≥ 2 previous ineffective cardioversion sessions in case of undetermined AF duration
  • Severe obesity ( > 40)
  • Very dilated Left Atrium (LA)(e.g. LA diameter > 60 mm and/or LA surface > 40 cm2 determined by 2D echocardiography)
  • Patients with AF secondary to an obvious reversible cause
  • Inadequate anticoagulation as defined in the inclusion criteria
  • LA thrombus on Transesophageal Echocardiography (TEE) or CT Scan prior to procedure
  • to anticoagulation (heparin, warfarin or NOAC)
  • Patients who are or may potentially be pregnant
  • Previous surgical or catheter ablation for AF
  • Any cardiac surgery within the past 2 months (60 days) (includes PCI)
  • Myocardial infarction within the past 2 months (60 days)
  • Previous atrioventricular valve surgery
  • History of blood clotting or bleeding abnormalities
  • Documented arterial thromboembolic event (including ) within the past 12 months (365 days)
  • Rheumatic Heart Disease
  • Chronic severe Heart Failure ( functional class IV and/or \< 25%)
  • Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days)
  • Unstable angina within the past month
  • Acute illness or active systemic infection or sepsis
  • AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
  • Diagnosed atrial myxoma
  • Significant severe pulmonary disease, (e.g. patients with restrictive pulmonary disease, constrictive or in GOLD stage IV) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms (e.g. unstable or untreated sleep apnea)
  • Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment
  • Enrollment in an study evaluating another device, biologic, or drug
  • Presence of intramural thrombus, tumor or other abnormality or condition that precludes vascular access, or manipulation of the catheter
  • or other disease processes likely to limit survival to less than 12 months
  • Acute Covid-19 infection (fever and/or biological inflammatory syndrome, and positive test documented)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
377 participants (actual)

Study arms

  • Experimental
    Tailored

    Tailored ablation strategy

    Procedure: Dispersion ablation + PVI · Device: VX1

  • Active comparator
    Anatomical

    Anatomical ablation strategy

    Procedure: PVI

Interventions

  • ProcedureDispersion ablation + PVI

    Ablation of spatio-temporal dispersion electrograms in combination with pulmonary vein antrum isolation

  • DeviceVX1

    VX1-based dispersion mapping

  • ProcedurePVI

    Pulmonary vein antrum isolation

06

What researchers measure

Primary outcomes

  1. Number of Participants Free From Documented AF After One Ablation Procedure

    Freedom from documented AF episodes \> 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure

    Time frame: 12 months

Secondary outcomes

  1. Number of Participants Free From Documented AF/AT After One or Two Ablation Procedures

    Freedom from documented AF/AT episodes \> 30 seconds, after one or two procedures, with or without AADs, at 12 months

    Time frame: 12 months

  2. Number of Participants Free From Documented AF/AT After One Ablation Procedure

    Freedom from documented AF/AT episodes \> 30 seconds, with or without AADs, 12 months after a single ablation procedure

    Time frame: 12 months

  3. Number of Participants With Complications (Safety Composite Endpoint)

    Complications at 12 months: death, cerebrovascular events, or serious treatment-related adverse event

    Time frame: 12 months

07

Results

Posted Sep 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneTailoredAnatomical
Started188186
Completed174174
Not completed1412

Outcome measures

PrimaryNumber of Participants Free From Documented AF After One Ablation Procedure

Freedom from documented AF episodes \> 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants Free From Documented AF After One Ablation Procedure
ParticipantsTailoredAnatomical
Number of Participants Free From Documented AF After One Ablation Procedure158124
SecondaryNumber of Participants Free From Documented AF/AT After One or Two Ablation Procedures

Freedom from documented AF/AT episodes \> 30 seconds, after one or two procedures, with or without AADs, at 12 months

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants Free From Documented AF/AT After One or Two Ablation Procedures
ParticipantsTailoredAnatomical
Number of Participants Free From Documented AF/AT After One or Two Ablation Procedures136126
SecondaryNumber of Participants Free From Documented AF/AT After One Ablation Procedure

Freedom from documented AF/AT episodes \> 30 seconds, with or without AADs, 12 months after a single ablation procedure

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants Free From Documented AF/AT After One Ablation Procedure
ParticipantsTailoredAnatomical
Number of Participants Free From Documented AF/AT After One Ablation Procedure108106
SecondaryNumber of Participants With Complications (Safety Composite Endpoint)

Complications at 12 months: death, cerebrovascular events, or serious treatment-related adverse event

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With Complications (Safety Composite Endpoint)
ParticipantsTailoredAnatomical
Number of Participants With Complications (Safety Composite Endpoint)85

Adverse events

Collected over 1 year after the study index ablation procedure. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tailored2/187 (1.1%)21/187 (11.2%)12/187 (6.4%)
Anatomical0/183 (0%)11/183 (6%)10/183 (5.5%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventTailoredAnatomical
Fluid overloadCardiac disorders9/1873/183
Pericarditis or pericardial effusionCardiac disorders4/1870/183
Vascular access complicationsVascular disorders3/1873/183
Cardiac tamponade or perforationCardiac disorders2/1872/183
BradycardiaCardiac disorders1/1871/183
Severe cardiac decompensationCardiac disorders1/1871/183
Puncture-site hemorrhageVascular disorders0/1871/183
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/1871/183
Abnormal ECG requiring hospitalizationCardiac disorders0/1871/183
Transient phrenic nerve palsyNervous system disorders1/1870/183
Most frequent other events
Most frequent other events
EventTailoredAnatomical
Covid-19Infections and infestations12/18710/183

Baseline characteristics

The baseline safety population included all randomized participants who underwent their first ablation procedure.

Age, Continuous
Age, Continuous(years)TailoredAnatomicalTotal
Mean66.4 ± 8.564.9 ± 8.565.7 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)TailoredAnatomicalTotal
Female423577
Male145148293
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)TailoredAnatomicalTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)TailoredAnatomicalTotal
Netherlands325
Belgium6410
United States293059
France128124252
Germany212344
08

Study locations

26 sites
  • Grandview Medical Center
    Birmingham, Alabama 35243, United States
  • Ascension St. Vincent's
    Jacksonville, Florida 32204, United States
  • Washington University
    St Louis, Missouri 63130, United States
  • Northwell Health
    New York, New York 10075, United States
  • New York Presbyterian Queens Hospital
    Queens, New York 11355, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Inova Fairfax
    Falls Church, Virginia 22042, United States
  • OLV Aalst
    Aalst, 9300, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Pôle Santé République
    Clermont-Ferrand, 63000, France
  • Hôpital Saint Philibert
    Lomme, 59462, France
  • Hôpital Louis Pradel - Hospices Civils de Lyon
    Lyon, 69677, France
  • Hôpital Saint-Joseph
    Marseille, 13008, France
  • Hôpital Privé Jacques Cartier
    Massy, 91300, France
  • Hôpital Privé du Confluent
    Nantes, 44200, France
  • Clinique Saint George
    Nice, 06105, France
  • Centre Cardiologique du Nord
    Saint-Denis, 93200, France
  • Clinique Rhéna
    Strasbourg, 67000, France
  • Clinique Pasteur
    Toulouse, 31076, France
  • CHRU Nancy
    Vandœuvre-lès-Nancy, 54511, France
  • Klinikum Coburg
    Coburg, 96450, Germany
  • Städtisches Klinikum Karlsruhe
    Karlsruhe, 76133, Germany
  • Deutsches Herzzentrum München
    München, 80636, Germany
  • OLVG Amsterdam
    Amsterdam, 1091, Netherlands
  • Isala Hartcentrum Zwolle
    Zwolle, 8025, Netherlands
09

References and documents

Publications

  • Seitz J, Bars C, Theodore G, Beurtheret S, Lellouche N, Bremondy M, Ferracci A, Faure J, Penaranda G, Yamazaki M, Avula UM, Curel L, Siame S, Berenfeld O, Pisapia A, Kalifa J. AF Ablation Guided by Spatiotemporal Electrogram Dispersion Without Pulmonary Vein Isolation: A Wholly Patient-Tailored Approach. J Am Coll Cardiol. 2017 Jan 24;69(3):303-321. doi: 10.1016/j.jacc.2016.10.065. PubMed 28104073 ↗
  • Seitz J, Durdez TM, Albenque JP, Pisapia A, Gitenay E, Durand C, Monteau J, Moubarak G, Theodore G, Lepillier A, Zhao A, Bremondy M, Maluski A, Cauchemez B, Combes S, Guyomar Y, Heuls S, Thomas O, Penaranda G, Siame S, Appetiti A, Milpied P, Bars C, Kalifa J. Artificial intelligence software standardizes electrogram-based ablation outcome for persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2022 Nov;33(11):2250-2260. doi: 10.1111/jce.15657. Epub 2022 Sep 18. PubMed 35989543 ↗
  • Deisenhofer I, Albenque JP, Busch S, Gitenay E, Mountantonakis SE, Roux A, Horvilleur J, Bakouboula B, Oza S, Abbey S, Theodore G, Lepillier A, Guyomar Y, Bessiere F, Jan Smit J, Mohr Durdez T, Milpied P, Appetiti A, Guerrero D, De Potter T, De Chillou C, Goldbarg S, Verma A, Hummel JD; TAILORED-AF Investigators. Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial. Nat Med. 2025 Apr;31(4):1286-1293. doi: 10.1038/s41591-025-03517-w. Epub 2025 Feb 14. PubMed 39953289 ↗
  • Deisenhofer I, Seitz J, Nguyen-Tu MS, Lotteau S, Bars C, Albenque JP, Busch S, Gitenay E, Mountantonakis S, Roux A, Horvilleur J, Bakouboula B, Oza S, Abbey S, Theodore G, Lepillier A, Guyomar Y, Bessiere F, Smit JJ, Rajendra A, Cooper DH, Rashid H, De Potter T, De Chillou C, Goldbarg S, Verma A, Morales G, Milpied P, Hummel JD, Kalifa J. Women with persistent atrial fibrillation need more than pulmonary vein isolation: personalised extra-pulmonary vein ablation strategy vs. pulmonary vein isolation alone in the TAILORED-AF trial. Europace. 2025 Oct 31;27(11):euaf281. doi: 10.1093/europace/euaf281. PubMed 41311304 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Dec 2023, 34 months.

Results were first posted in Sep 2025, 1 year 8 months after primary completion.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 34 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 8, 2021
StartActual
Feb 12, 2021
Primary completionActual
Dec 27, 2023
CompletionActual
Dec 27, 2023
Results first posted
Sep 12, 2025
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04702451
Lead sponsor
Volta Medical
Collaborators
Fortrea, CardiaBase
Responsible party
Sponsor
First posted
Jan 8, 2021
Start date
Feb 12, 2021
Primary completion
Dec 27, 2023
Completion
Dec 27, 2023
Results posted
Sep 12, 2025
Last update
Sep 12, 2025

Study contacts

Isabel Deisenhofer, MD
study chair · Deutsches Herzzentrum Muenchen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion